| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 19 | 2023 | 5767 | 2.420 |
Why?
|
| Receptors, Somatostatin | 7 | 2013 | 85 | 2.370 |
Why?
|
| Prostate-Specific Antigen | 6 | 2023 | 993 | 2.360 |
Why?
|
| Magnetic Resonance Imaging | 34 | 2023 | 7702 | 2.060 |
Why?
|
| Diagnostic Imaging | 11 | 2021 | 1162 | 2.000 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 8 | 2020 | 341 | 1.920 |
Why?
|
| Image Enhancement | 7 | 2017 | 561 | 1.290 |
Why?
|
| Multidetector Computed Tomography | 2 | 2022 | 150 | 1.190 |
Why?
|
| Contrast Media | 13 | 2022 | 1472 | 1.130 |
Why?
|
| Carcinoid Tumor | 3 | 2013 | 280 | 1.100 |
Why?
|
| Prostate | 4 | 2023 | 1088 | 1.090 |
Why?
|
| Indocyanine Green | 4 | 2023 | 117 | 1.060 |
Why?
|
| Kidney Neoplasms | 6 | 2021 | 3022 | 1.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2019 | 305 | 0.990 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2021 | 2326 | 0.980 |
Why?
|
| Mice, Nude | 24 | 2021 | 4307 | 0.960 |
Why?
|
| Octreotide | 6 | 2019 | 118 | 0.950 |
Why?
|
| Peritonitis, Tuberculous | 1 | 2023 | 10 | 0.930 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2023 | 11 | 0.920 |
Why?
|
| Gene Transfer Techniques | 5 | 2013 | 716 | 0.900 |
Why?
|
| Whole Body Imaging | 6 | 2020 | 114 | 0.880 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 27 | 0.830 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 1390 | 0.810 |
Why?
|
| Ethanol | 1 | 2023 | 264 | 0.800 |
Why?
|
| Adnexal Diseases | 1 | 2021 | 30 | 0.780 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2016 | 592 | 0.770 |
Why?
|
| Sensitivity and Specificity | 13 | 2022 | 4971 | 0.770 |
Why?
|
| Kallikreins | 1 | 2021 | 84 | 0.760 |
Why?
|
| Genetic Therapy | 3 | 2013 | 1616 | 0.750 |
Why?
|
| Radiopharmaceuticals | 9 | 2023 | 1301 | 0.750 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2023 | 7551 | 0.740 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2011 | 196 | 0.730 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 187 | 0.700 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 136 | 0.700 |
Why?
|
| Ovarian Neoplasms | 12 | 2021 | 4638 | 0.670 |
Why?
|
| Kidney | 5 | 2021 | 2146 | 0.660 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 148 | 0.660 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2017 | 7 | 0.630 |
Why?
|
| Chromatin | 1 | 2023 | 942 | 0.620 |
Why?
|
| Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2017 | 13 | 0.620 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2013 | 600 | 0.620 |
Why?
|
| Humans | 91 | 2023 | 261506 | 0.610 |
Why?
|
| Neuroendocrine Tumors | 2 | 2022 | 634 | 0.600 |
Why?
|
| Neoplasms, Experimental | 4 | 2009 | 750 | 0.560 |
Why?
|
| Endometrial Neoplasms | 2 | 2016 | 1341 | 0.560 |
Why?
|
| Mice | 46 | 2021 | 34495 | 0.550 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2023 | 833 | 0.550 |
Why?
|
| Biopsy | 7 | 2023 | 3443 | 0.540 |
Why?
|
| Myometrium | 1 | 2015 | 79 | 0.520 |
Why?
|
| Drug Monitoring | 1 | 2017 | 333 | 0.520 |
Why?
|
| Neovascularization, Pathologic | 10 | 2021 | 1547 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 10035 | 0.510 |
Why?
|
| Genetic Vectors | 5 | 2013 | 1694 | 0.500 |
Why?
|
| Neoplasms | 11 | 2023 | 15193 | 0.500 |
Why?
|
| Bone Neoplasms | 9 | 2021 | 2576 | 0.490 |
Why?
|
| Animals | 52 | 2021 | 59536 | 0.490 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2017 | 962 | 0.490 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 400 | 0.490 |
Why?
|
| Diagnosis, Differential | 7 | 2021 | 4744 | 0.470 |
Why?
|
| Prostatectomy | 4 | 2023 | 962 | 0.460 |
Why?
|
| Cell Line, Tumor | 25 | 2021 | 14551 | 0.450 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2013 | 103 | 0.450 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 221 | 0.440 |
Why?
|
| Bevacizumab | 2 | 2021 | 938 | 0.440 |
Why?
|
| Adenoviridae | 3 | 2013 | 1459 | 0.430 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2023 | 624 | 0.430 |
Why?
|
| Perfusion Imaging | 2 | 2012 | 30 | 0.420 |
Why?
|
| Male | 38 | 2023 | 123000 | 0.420 |
Why?
|
| Positron-Emission Tomography | 8 | 2023 | 2173 | 0.420 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2015 | 1248 | 0.420 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 5112 | 0.420 |
Why?
|
| Prostatic Hyperplasia | 1 | 2013 | 210 | 0.410 |
Why?
|
| Body Burden | 1 | 2011 | 65 | 0.410 |
Why?
|
| Liver Circulation | 1 | 2011 | 35 | 0.400 |
Why?
|
| Neoplasm Transplantation | 7 | 2019 | 1519 | 0.400 |
Why?
|
| Gelatin | 1 | 2011 | 49 | 0.390 |
Why?
|
| Acrylic Resins | 1 | 2011 | 43 | 0.390 |
Why?
|
| Chemotaxis | 4 | 1995 | 138 | 0.390 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 6009 | 0.390 |
Why?
|
| Disease Models, Animal | 10 | 2021 | 7222 | 0.390 |
Why?
|
| Bone and Bones | 3 | 2014 | 619 | 0.390 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 568 | 0.390 |
Why?
|
| Fluorescent Dyes | 3 | 2023 | 459 | 0.380 |
Why?
|
| Microspheres | 1 | 2011 | 210 | 0.380 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2012 | 192 | 0.370 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2012 | 172 | 0.370 |
Why?
|
| Drug Carriers | 2 | 2011 | 327 | 0.370 |
Why?
|
| Safety Management | 1 | 2011 | 132 | 0.370 |
Why?
|
| Radiation Protection | 1 | 2011 | 205 | 0.370 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2012 | 223 | 0.370 |
Why?
|
| Angiotensin II | 1 | 2011 | 198 | 0.360 |
Why?
|
| Hepatic Artery | 1 | 2011 | 240 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 1833 | 0.360 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2011 | 181 | 0.350 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2016 | 1648 | 0.350 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 141 | 0.350 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 239 | 0.350 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 2341 | 0.330 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 13658 | 0.330 |
Why?
|
| Bromovirus | 2 | 2020 | 3 | 0.330 |
Why?
|
| Population Surveillance | 2 | 2014 | 627 | 0.330 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2010 | 255 | 0.320 |
Why?
|
| Sulfonamides | 1 | 2017 | 1823 | 0.320 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2016 | 361 | 0.310 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 1823 | 0.300 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 726 | 0.300 |
Why?
|
| Echo-Planar Imaging | 1 | 2008 | 73 | 0.300 |
Why?
|
| Gamma Cameras | 3 | 2013 | 40 | 0.300 |
Why?
|
| Genes, Reporter | 4 | 2013 | 798 | 0.300 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2010 | 925 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 585 | 0.290 |
Why?
|
| Tumor Cells, Cultured | 8 | 2014 | 5395 | 0.280 |
Why?
|
| Rabbits | 3 | 2013 | 957 | 0.280 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 1995 | 157 | 0.270 |
Why?
|
| Mice, SCID | 6 | 2021 | 1869 | 0.270 |
Why?
|
| Nanoparticles | 5 | 2020 | 554 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2013 | 5319 | 0.270 |
Why?
|
| Aged | 20 | 2021 | 70117 | 0.270 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 10331 | 0.270 |
Why?
|
| Female | 38 | 2021 | 141928 | 0.260 |
Why?
|
| Molecular Imaging | 3 | 2017 | 185 | 0.260 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3578 | 0.260 |
Why?
|
| Optical Imaging | 5 | 2020 | 157 | 0.250 |
Why?
|
| Pyrimidines | 1 | 2017 | 3518 | 0.250 |
Why?
|
| Tumor Burden | 5 | 2020 | 1987 | 0.250 |
Why?
|
| Thoracic Neoplasms | 1 | 2008 | 337 | 0.250 |
Why?
|
| Middle Aged | 21 | 2021 | 86204 | 0.250 |
Why?
|
| Lung Neoplasms | 7 | 2020 | 11538 | 0.240 |
Why?
|
| Indicator Dilution Techniques | 1 | 2023 | 22 | 0.240 |
Why?
|
| Doxorubicin | 1 | 2011 | 3005 | 0.240 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2019 | 209 | 0.240 |
Why?
|
| Abdomen, Acute | 1 | 2003 | 36 | 0.230 |
Why?
|
| Pelvic Neoplasms | 1 | 2005 | 189 | 0.230 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2020 | 882 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2014 | 8873 | 0.220 |
Why?
|
| Abdominal Neoplasms | 1 | 2005 | 231 | 0.220 |
Why?
|
| Pancreatic Cyst | 1 | 2023 | 107 | 0.220 |
Why?
|
| Tissue Distribution | 3 | 2013 | 875 | 0.220 |
Why?
|
| Gene Library | 1 | 2023 | 294 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 4 | 2015 | 3981 | 0.210 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2023 | 518 | 0.210 |
Why?
|
| Tetraspanin 30 | 1 | 2021 | 14 | 0.210 |
Why?
|
| Telomerase | 1 | 2005 | 525 | 0.200 |
Why?
|
| Metformin | 2 | 2019 | 378 | 0.200 |
Why?
|
| Skin | 2 | 2021 | 1259 | 0.200 |
Why?
|
| Peritoneum | 1 | 2022 | 150 | 0.200 |
Why?
|
| Water | 1 | 2023 | 361 | 0.200 |
Why?
|
| Polymers | 2 | 2014 | 223 | 0.200 |
Why?
|
| Abdomen | 1 | 2023 | 332 | 0.200 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2021 | 36 | 0.200 |
Why?
|
| Neoplasm Grading | 3 | 2022 | 1742 | 0.200 |
Why?
|
| Fluorescence | 2 | 2018 | 195 | 0.190 |
Why?
|
| Pelvis | 1 | 2023 | 362 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2020 | 3821 | 0.190 |
Why?
|
| Radionuclide Imaging | 3 | 2013 | 660 | 0.190 |
Why?
|
| Phantoms, Imaging | 2 | 2016 | 1271 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2023 | 37905 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2004 | 529 | 0.180 |
Why?
|
| Signal Transduction | 9 | 2021 | 11965 | 0.180 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 821 | 0.180 |
Why?
|
| Pancreas | 1 | 2023 | 718 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2011 | 1555 | 0.180 |
Why?
|
| Algorithms | 4 | 2023 | 3890 | 0.180 |
Why?
|
| Adult | 15 | 2017 | 77950 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 135 | 0.170 |
Why?
|
| Green Fluorescent Proteins | 2 | 2013 | 694 | 0.170 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 324 | 0.170 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2021 | 425 | 0.170 |
Why?
|
| Radiation Dosage | 3 | 2016 | 1014 | 0.170 |
Why?
|
| Nanostructures | 2 | 2017 | 94 | 0.160 |
Why?
|
| Intestine, Small | 1 | 2022 | 499 | 0.160 |
Why?
|
| HCT116 Cells | 1 | 2019 | 348 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 2 | 2020 | 2518 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2021 | 182 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2017 | 1756 | 0.160 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4557 | 0.160 |
Why?
|
| Ultrasonography | 3 | 2023 | 1863 | 0.150 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 133 | 0.150 |
Why?
|
| Chimera | 2 | 2009 | 145 | 0.150 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 1995 | 104 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2020 | 842 | 0.150 |
Why?
|
| Urography | 1 | 2016 | 43 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 615 | 0.150 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14289 | 0.150 |
Why?
|
| Cell Proliferation | 9 | 2021 | 7226 | 0.140 |
Why?
|
| Metal Nanoparticles | 1 | 2018 | 164 | 0.140 |
Why?
|
| Prognosis | 3 | 2021 | 21713 | 0.140 |
Why?
|
| Cerebellar Neoplasms | 1 | 2021 | 434 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 1533 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2016 | 12873 | 0.140 |
Why?
|
| Transplantation, Heterologous | 4 | 2020 | 1082 | 0.140 |
Why?
|
| Feasibility Studies | 4 | 2015 | 2292 | 0.140 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 1029 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2013 | 3536 | 0.140 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 4844 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2021 | 540 | 0.130 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2016 | 132 | 0.130 |
Why?
|
| Indazoles | 1 | 2017 | 297 | 0.130 |
Why?
|
| Linear Models | 2 | 2009 | 1085 | 0.130 |
Why?
|
| Endometrium | 2 | 2016 | 470 | 0.130 |
Why?
|
| Osteoblasts | 3 | 2014 | 370 | 0.130 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2014 | 15 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 1226 | 0.130 |
Why?
|
| Cardiac Glycosides | 1 | 2014 | 16 | 0.130 |
Why?
|
| Nerium | 1 | 2014 | 12 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2016 | 209 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2007 | 6869 | 0.130 |
Why?
|
| Ureter | 1 | 2016 | 209 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mos | 1 | 1994 | 16 | 0.120 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1994 | 36 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 402 | 0.120 |
Why?
|
| Microvessels | 1 | 2015 | 135 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 246 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2016 | 247 | 0.120 |
Why?
|
| Renal Veins | 1 | 2014 | 56 | 0.120 |
Why?
|
| Gadolinium | 2 | 2018 | 164 | 0.120 |
Why?
|
| Breast Neoplasms | 5 | 2013 | 15694 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 2291 | 0.120 |
Why?
|
| Cardiac Tamponade | 1 | 2014 | 51 | 0.120 |
Why?
|
| Biomimetics | 1 | 2014 | 33 | 0.120 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2014 | 36 | 0.120 |
Why?
|
| Liposomes | 2 | 2013 | 684 | 0.120 |
Why?
|
| Indium Radioisotopes | 1 | 2013 | 65 | 0.120 |
Why?
|
| Biomimetic Materials | 1 | 2014 | 41 | 0.120 |
Why?
|
| Injections, Intra-Arterial | 1 | 2013 | 62 | 0.120 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 60 | 0.120 |
Why?
|
| Quinolones | 1 | 2014 | 160 | 0.110 |
Why?
|
| Osteosarcoma | 1 | 2020 | 929 | 0.110 |
Why?
|
| Organ Size | 2 | 2013 | 690 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 483 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 550 | 0.110 |
Why?
|
| Injections, Intralesional | 1 | 2013 | 164 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1664 | 0.110 |
Why?
|
| Femur | 2 | 2011 | 158 | 0.110 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2011 | 204 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2013 | 185 | 0.110 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 151 | 0.110 |
Why?
|
| 3T3 Cells | 5 | 1997 | 355 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2022 | 2967 | 0.110 |
Why?
|
| Intracranial Hypertension | 1 | 2014 | 119 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2014 | 215 | 0.110 |
Why?
|
| Optics and Photonics | 1 | 2014 | 146 | 0.110 |
Why?
|
| Emergencies | 1 | 2014 | 202 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2020 | 1154 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 190 | 0.110 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 95 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 785 | 0.110 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2014 | 156 | 0.110 |
Why?
|
| Phosphorylcholine | 2 | 2012 | 54 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 1959 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 1946 | 0.100 |
Why?
|
| Infusions, Intralesional | 1 | 2011 | 9 | 0.100 |
Why?
|
| Intestinal Obstruction | 1 | 2014 | 202 | 0.100 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 941 | 0.100 |
Why?
|
| Necrosis | 1 | 2013 | 580 | 0.100 |
Why?
|
| Plasmids | 1 | 2013 | 837 | 0.100 |
Why?
|
| Ethiodized Oil | 1 | 2011 | 15 | 0.100 |
Why?
|
| Deoxyglucose | 1 | 2011 | 115 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 769 | 0.100 |
Why?
|
| Ileal Neoplasms | 1 | 2011 | 47 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2014 | 428 | 0.100 |
Why?
|
| Transgenes | 1 | 2013 | 557 | 0.100 |
Why?
|
| Heterografts | 1 | 2013 | 733 | 0.100 |
Why?
|
| ras Proteins | 1 | 1995 | 770 | 0.100 |
Why?
|
| Lysophospholipids | 2 | 2006 | 147 | 0.100 |
Why?
|
| Liver Function Tests | 1 | 2011 | 173 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 15862 | 0.100 |
Why?
|
| Bronchial Neoplasms | 1 | 2011 | 79 | 0.090 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 1245 | 0.090 |
Why?
|
| Cytomegalovirus | 1 | 2013 | 482 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 329 | 0.090 |
Why?
|
| Gadolinium DTPA | 2 | 2008 | 172 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 151 | 0.090 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 229 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 4892 | 0.090 |
Why?
|
| Calcification, Physiologic | 1 | 2010 | 56 | 0.090 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2011 | 153 | 0.090 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 160 | 0.090 |
Why?
|
| Cell Transformation, Viral | 1 | 1990 | 138 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2020 | 32848 | 0.090 |
Why?
|
| Cell Line | 5 | 2011 | 5114 | 0.090 |
Why?
|
| Hydrolases | 1 | 1990 | 123 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 475 | 0.090 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.090 |
Why?
|
| Prodrugs | 2 | 2008 | 217 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2014 | 712 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2015 | 1026 | 0.090 |
Why?
|
| Nephrectomy | 1 | 2014 | 779 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2012 | 1546 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1331 | 0.080 |
Why?
|
| Acute Disease | 1 | 2014 | 2422 | 0.080 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 105 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1995 | 2488 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 664 | 0.080 |
Why?
|
| Chromones | 1 | 2008 | 120 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1546 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 7789 | 0.080 |
Why?
|
| Lysosomes | 1 | 1990 | 347 | 0.080 |
Why?
|
| Pyrroles | 1 | 2011 | 576 | 0.080 |
Why?
|
| Radiography | 2 | 2009 | 1904 | 0.080 |
Why?
|
| Somatostatin | 1 | 2007 | 114 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 519 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 461 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2011 | 423 | 0.070 |
Why?
|
| Bone Density | 1 | 2010 | 476 | 0.070 |
Why?
|
| Apoptosis | 4 | 2015 | 7591 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2007 | 234 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2008 | 271 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 691 | 0.070 |
Why?
|
| Sphingosine | 1 | 2006 | 55 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2007 | 249 | 0.070 |
Why?
|
| Phototherapy | 2 | 2018 | 75 | 0.070 |
Why?
|
| Serine | 1 | 2007 | 388 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2007 | 168 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2011 | 992 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2008 | 429 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2012 | 2218 | 0.070 |
Why?
|
| Mitosis | 1 | 2007 | 615 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 501 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 1242 | 0.060 |
Why?
|
| ras GTPase-Activating Proteins | 2 | 1995 | 30 | 0.060 |
Why?
|
| Myocardium | 1 | 2011 | 1313 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2010 | 769 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 2 | 2014 | 5061 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 1995 | 80 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 673 | 0.060 |
Why?
|
| Texas | 2 | 2007 | 6311 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2011 | 1682 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3639 | 0.060 |
Why?
|
| GTPase-Activating Proteins | 2 | 1995 | 126 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 672 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1033 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 2307 | 0.060 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 2314 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 697 | 0.060 |
Why?
|
| Breast | 1 | 2010 | 1344 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 1879 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 588 | 0.060 |
Why?
|
| Abdominal Injuries | 1 | 2003 | 80 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2011 | 1471 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 1489 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2011 | 1202 | 0.050 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 305 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2008 | 878 | 0.050 |
Why?
|
| Taxoids | 3 | 2012 | 967 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2003 | 209 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 852 | 0.050 |
Why?
|
| Protein Binding | 2 | 2007 | 3438 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 840 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2002 | 39 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 1506 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1374 | 0.050 |
Why?
|
| Lectins | 1 | 2002 | 151 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 2027 | 0.050 |
Why?
|
| Nanotechnology | 2 | 2014 | 137 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2003 | 462 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1363 | 0.050 |
Why?
|
| Clone Cells | 1 | 2002 | 555 | 0.050 |
Why?
|
| Glioma | 1 | 2012 | 1963 | 0.050 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 164 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 4078 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 385 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2007 | 1996 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 257 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 272 | 0.050 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 94 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2003 | 575 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2012 | 9244 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 208 | 0.040 |
Why?
|
| Prevalence | 1 | 2007 | 3260 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 1062 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 2947 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2006 | 1000 | 0.040 |
Why?
|
| Cisplatin | 1 | 2006 | 2432 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2005 | 2588 | 0.040 |
Why?
|
| Copper Radioisotopes | 1 | 2019 | 31 | 0.040 |
Why?
|
| Stromal Cells | 2 | 2014 | 825 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 842 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 1995 | 2927 | 0.040 |
Why?
|
| Receptors, Peptide | 1 | 2019 | 86 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2007 | 1423 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2018 | 50 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 4367 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2009 | 2819 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 884 | 0.040 |
Why?
|
| Manganese | 1 | 2018 | 80 | 0.040 |
Why?
|
| Mutation | 2 | 2015 | 15179 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 573 | 0.040 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 333 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2014 | 2074 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2020 | 691 | 0.040 |
Why?
|
| Biological Transport | 1 | 2019 | 597 | 0.040 |
Why?
|
| United States | 2 | 2011 | 15433 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 2864 | 0.040 |
Why?
|
| Time Factors | 5 | 2011 | 12926 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2019 | 305 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2020 | 875 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2012 | 5178 | 0.040 |
Why?
|
| Capsid | 1 | 2017 | 103 | 0.040 |
Why?
|
| CHO Cells | 2 | 1994 | 311 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2017 | 234 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 7548 | 0.040 |
Why?
|
| Gold | 1 | 2018 | 270 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2016 | 117 | 0.040 |
Why?
|
| Proteins | 2 | 1995 | 1963 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 1997 | 264 | 0.030 |
Why?
|
| Dynamic Light Scattering | 1 | 2015 | 9 | 0.030 |
Why?
|
| Cricetinae | 2 | 1994 | 706 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 14889 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2015 | 52 | 0.030 |
Why?
|
| ras-GRF1 | 1 | 1995 | 8 | 0.030 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 1995 | 6 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 1997 | 311 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1997 | 254 | 0.030 |
Why?
|
| Cell Movement | 2 | 2013 | 2466 | 0.030 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 1995 | 47 | 0.030 |
Why?
|
| Tyrosine | 2 | 1994 | 498 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1995 | 80 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2015 | 209 | 0.030 |
Why?
|
| Iron | 1 | 2018 | 376 | 0.030 |
Why?
|
| Fibronectins | 1 | 1995 | 197 | 0.030 |
Why?
|
| Random Allocation | 2 | 2006 | 703 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 276 | 0.030 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1974 | 10 | 0.030 |
Why?
|
| Oncogene Protein gp140(v-fms) | 1 | 1994 | 1 | 0.030 |
Why?
|
| Oncogene Proteins v-sis | 1 | 1994 | 1 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 3230 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fes | 1 | 1994 | 2 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2015 | 208 | 0.030 |
Why?
|
| Carcinoma | 1 | 2006 | 2578 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 1995 | 134 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2015 | 173 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2007 | 1678 | 0.030 |
Why?
|
| Intrauterine Devices | 1 | 1974 | 19 | 0.030 |
Why?
|
| Transfection | 2 | 2011 | 2944 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1995 | 159 | 0.030 |
Why?
|
| Type C Phospholipases | 1 | 1994 | 53 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 2054 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2014 | 223 | 0.030 |
Why?
|
| Time | 1 | 1974 | 178 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 1994 | 97 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 1529 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 1974 | 119 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1516 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1994 | 129 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 4143 | 0.030 |
Why?
|
| Young Adult | 3 | 2016 | 21445 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2011 | 1048 | 0.030 |
Why?
|
| Genes, ras | 1 | 2015 | 667 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2012 | 32 | 0.030 |
Why?
|
| Protein Kinases | 1 | 1997 | 874 | 0.030 |
Why?
|
| Pericytes | 1 | 2013 | 96 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 5637 | 0.030 |
Why?
|
| Cattle | 1 | 1994 | 783 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2013 | 227 | 0.030 |
Why?
|
| Lymphography | 1 | 2011 | 51 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2009 | 4233 | 0.030 |
Why?
|
| Arabinofuranosyluracil | 1 | 2011 | 42 | 0.030 |
Why?
|
| Research | 1 | 1974 | 415 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 848 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 2011 | 87 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 1994 | 478 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 671 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2011 | 193 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 113 | 0.020 |
Why?
|
| Cytophotometry | 1 | 1990 | 6 | 0.020 |
Why?
|
| beta-Glucosidase | 1 | 1990 | 5 | 0.020 |
Why?
|
| Acridine Orange | 1 | 1990 | 10 | 0.020 |
Why?
|
| Povidone | 1 | 1990 | 13 | 0.020 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 1990 | 19 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 1990 | 59 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 6089 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2011 | 2669 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 1990 | 68 | 0.020 |
Why?
|
| Cell Transdifferentiation | 1 | 2011 | 112 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2013 | 519 | 0.020 |
Why?
|
| Risk Factors | 1 | 2007 | 17523 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1990 | 108 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 143 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 292 | 0.020 |
Why?
|
| Biomarkers | 2 | 2012 | 5047 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 29902 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1990 | 394 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 503 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 408 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1994 | 661 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1990 | 137 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2010 | 160 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 182 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 180 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 355 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 612 | 0.020 |
Why?
|
| Uterus | 1 | 1974 | 678 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 702 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 9180 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 1353 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2010 | 245 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1990 | 429 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 2084 | 0.020 |
Why?
|
| Base Sequence | 2 | 2010 | 4917 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 677 | 0.020 |
Why?
|
| Phosphorylation | 3 | 2007 | 4804 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2011 | 560 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1399 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2008 | 214 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 650 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 3869 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 241 | 0.020 |
Why?
|
| Insulin | 1 | 1994 | 1454 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1141 | 0.020 |
Why?
|
| Keratins | 1 | 2008 | 330 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 837 | 0.020 |
Why?
|
| Vimentin | 1 | 2008 | 253 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 197 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1541 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 586 | 0.020 |
Why?
|
| G2 Phase | 1 | 2007 | 206 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 342 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 334 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 2007 | 135 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 943 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 521 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 5437 | 0.020 |
Why?
|
| Terbutaline | 1 | 2006 | 27 | 0.020 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2006 | 67 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2006 | 71 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 1022 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2006 | 231 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2006 | 127 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2007 | 886 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 5710 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 1182 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 1143 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 2370 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2006 | 334 | 0.020 |
Why?
|
| Child | 2 | 2017 | 29154 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 1149 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 3045 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 2104 | 0.020 |
Why?
|
| Adolescent | 2 | 2016 | 31252 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2006 | 621 | 0.020 |
Why?
|
| Phthalazines | 1 | 2006 | 253 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 1764 | 0.020 |
Why?
|
| Equipment Design | 1 | 2007 | 1204 | 0.010 |
Why?
|
| Models, Biological | 1 | 2013 | 3254 | 0.010 |
Why?
|
| Cell Division | 1 | 2007 | 2489 | 0.010 |
Why?
|
| Cholesterol | 1 | 2006 | 658 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 6086 | 0.010 |
Why?
|
| Vaccination | 1 | 2009 | 1123 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 5539 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2011 | 6150 | 0.010 |
Why?
|
| Binding Sites | 2 | 1997 | 2171 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10001 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 4938 | 0.010 |
Why?
|
| Pyridines | 1 | 2006 | 1244 | 0.010 |
Why?
|
| Cell Extracts | 1 | 1997 | 62 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1997 | 161 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1997 | 869 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 1997 | 359 | 0.010 |
Why?
|
| Population | 1 | 1974 | 27 | 0.010 |
Why?
|
| Physiology | 1 | 1974 | 17 | 0.010 |
Why?
|
| Hysterosalpingography | 1 | 1974 | 15 | 0.010 |
Why?
|
| Genitalia | 1 | 1974 | 46 | 0.010 |
Why?
|
| Family Planning Services | 1 | 1974 | 35 | 0.010 |
Why?
|
| Population Dynamics | 1 | 1974 | 42 | 0.010 |
Why?
|
| Urogenital System | 1 | 1974 | 59 | 0.010 |
Why?
|
| Contraception | 1 | 1974 | 49 | 0.010 |
Why?
|
| Biology | 1 | 1974 | 75 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 1974 | 68 | 0.010 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 1994 | 132 | 0.010 |
Why?
|
| Demography | 1 | 1974 | 435 | 0.010 |
Why?
|
| Disease | 1 | 1974 | 165 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1997 | 2483 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1994 | 1152 | 0.000 |
Why?
|